NMNilam S. Mangalmurti

Nilam S. Mangalmurti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nilam S. Mangalmurti has a total of 351 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Red Blood Cell Surface Defines a Distinct Tumor DNA Compartment for Liquid Biopsy

    by Elias Elias, Henry Ruger, Jarrod Predina, Benjamin A. Bleiberg, Phurin Areesawangkit, Estela Noguera-Ortega, Abhishek Kulkarni, Jeffrey C. Thompson, Michael G. S. Shashaty, Corey Langer, et al.

    Red blood cells (RBCs) modulate host inflammatory responses by scavenging mitochondrial and pathogen DNA. However, how RBC surface properties govern the capture of tumor-derived DNA remains poorly understood. We show that RBCs tether and retain tumor-derived DNA on their surface, forming a distinct circulating pool of RBC-bound tumor DNA (rtDNA). Desialylation increased DNA capture in a Toll-like receptor 9 (TLR9)-dependent manner, identifying RBC surface sialylation and TLR9 as regulators of DNA binding. In mice bearing lung cancer xenografts, rtDNA was detected in all animals and its abundance correlated with tumor burden, whereas tumor DNA was undetectable in matched plasma samples. In patients with lung cancer, the majority of detected mutant tumor DNA was associated with RBCs rather than plasma, and RBC-derived mutations were concordant with molecular alterations identified in matched tumor tissue. Collectively, these findings establish the RBC surface as a tunable site of tumor DNA capture and retention and challenge the plasma-centric paradigm of liquid biopsy by identifying a distinct cellular reservoir of tumor-derived genetic material.

  • Open Access

    Cell-free DNA methylomics identify tissue injury patterns in pediatric ARDS

    by Nadir Yehya, Jacob E. Till, Nishi Srivastava, Donglan Zhang, Jason D. Christie, Erica L. Carpenter, Nilam S. Mangalmurti, Wanding Zhou

    Plasma cell-free DNA can ientify what tissues are damaged in children with severe lung injury, allowing us to identify new avenues to target therapies.


  • Detection of Human Papillomavirus DNA on Red Blood Cells in Patients With Cervical Cancer

    by Sue Li, Emily Bs Oatman, Janos Tanyi, Sarah H. Md Kim, Lori Md Cory, Nilam S. Mangalmurti

    Red blood cells (RBCs) have the potential to bind and harbor viral DNA, providing a novel approach to detecting human papillomavirus (HPV). Red blood cells incubated with fluorescently labeled HPV CpG acquired HPV DNA in a concentration-dependent manner. Red blood cells incubated with HPV-positive cervical cancer cells (CaSki cell line) acquired HPV 16 DNA detected by quantitative polymerase chain reaction (PCR). Consistent with these results, HPV 16 DNA was detected by quantitative PCR on RBCs from five patients with cervical cancer or dysplasia but not on healthy control RBCs. Detection of HPV 16 DNA on RBCs from patients with cervical cancer underscores the potential of RBC-bound DNA as a substrate for future blood-based HPV screening.


  • Open Access

    Red blood cells capture and deliver bacterial DNA to drive host responses during polymicrobial sepsis

    by L.K. Metthew Lam, Nathan J. Klingensmith, Layal Sayegh, Emily Oatman, Joshua S. Jose, Christopher V. Cosgriff, Kaitlyn A. Eckart, John McGinniss, Piyush Ranjan, Matthew Lanza, et al.

    Red blood cells (RBCs), traditionally recognized for their role in transporting oxygen, play a pivotal role in the body’s immune response by expressing TLR9 and scavenging excess host cell-free DNA. DNA capture by RBCs leads to accelerated RBC clearance and triggers inflammation. Whether RBCs can also acquire microbial DNA during infections is unknown. Murine RBCs acquire microbial DNA in vitro, and bacterial DNA–induced (bDNA-induced) macrophage activation was augmented by WT, but not Tlr9-deleted, RBCs. In a mouse model of polymicrobial sepsis, RBC-bound bDNA was elevated in WT mice but not in erythroid Tlr9–deleted mice. Plasma cytokine analysis in these mice revealed distinct sepsis clusters characterized by persistent hypothermia and hyperinflammation in the most severely affected mice. RBC Tlr9 deletion attenuated plasma and tissue IL-6 production in the most severely affected group. Parallel findings in humans confirmed that RBCs from patients with sepsis harbored more bDNA than did RBCs from healthy individuals. Further analysis through 16S sequencing of RBC-bound DNA illustrated distinct microbial communities, with RBC-bound DNA composition correlating with plasma IL-6 in patients with sepsis. Collectively, these findings unveil RBCs as overlooked reservoirs and couriers of microbial DNA, capable of influencing host inflammatory responses in sepsis.


  • Open Access

    Human red blood cells express the RNA sensor TLR7

    by L. K. Metthew Lam, Emily Oatman, Kaitlyn A. Eckart, Nathan J. Klingensmith, Emily Flowers, Layal Sayegh, Julia Yuen, Rebecca L. Clements, Nuala J. Meyer, Kellie A. Jurado, et al.

    Red blood cells (RBCs) express the nucleic acid-binding toll-like receptor 9 (TLR9) and bind CpG-containing DNA. However, whether human RBCs express other nucleic acid-binding TLRs is unknown. Here we show that human RBCs express the RNA sensor TLR7. TLR7 is present on the red cell membrane and is associated with the RBC membrane protein Band 3. In patients with SARS-CoV2-associated sepsis, TLR7-Band 3 interactions in the RBC membrane are increased when compared with healthy controls. In vitro, RBCs bind synthetic ssRNA and RNA from ssRNA viruses. Thus, RBCs may serve as a previously unrecognized sink for exogenous RNA, expanding the repertoire of non-gas exchanging functions performed by RBCs.


  • Red blood cells function as reservoirs of tumor DNA

    by Jeffrey C. Thompson, Sue Li, Joshua S. Jose, Jarrod Predina, Aasha Gupta, Evgeniy Eruslanov, Sunil Singhal, Steven M. Albelda, Nilam S. Mangalmurti

    We present a novel method for lung cancer detection by revealing RBCs as a reservoir for tumor DNA, overcoming the limitations of current circulating tumor ctDNA methodologies. By demonstrating that RBCs can capture tumor DNA, including critical mutations found in lung cancer, we provide a promising, biopsy-free avenue for early cancer diagnostics. This discovery opens up exciting possibilities for developing RBC-based diagnostic tools, significantly enhancing the sensitivity and clinical utility of noninvasive cancer detection.


  • Open Access

    Red Blood Cell DNA Capture and Delivery Drives Host Responses During Polymicrobial Sepsis

    by Long Kwan Lam, Nathan Klingensmith, Layal Sayegh, Emily Oatman, Joshua Jose, Christopher Cosgriff, Kaitlyn Eckart, John McGinnis, Piyush Ranjan, Matthew Lanza, et al.

    Red blood cells (RBCs), traditionally recognized for their role in transporting oxygen, play a pivotal role in the body's immune response by expressing TLR9 and scavenging excess host cell-free DNA. DNA capture by RBCs leads to accelerated RBC clearance and triggers inflammation. Whether RBCs can also acquire microbial DNA during infections is unknown. Murine RBCs acquire microbial DNA in vitro and bacterial-DNA-induced macrophage activation was augmented by WT but not TLR9-deleted RBCs. In a mouse model of polymicrobial sepsis, RBC-bound bacterial DNA was elevated in WT but not in erythroid TLR9-deleted mice. Plasma cytokine analysis revealed distinct sepsis endotypes, characterized by persistent hypothermia and hyperinflammation in the most severely affected subjects. RBC-TLR9 deletion attenuated plasma and tissue IL-6 production in the most severe endotype. Parallel findings in human subjects confirmed that RBCs from septic patients harbored more bacterial DNA compared to healthy individuals. Further analysis through 16S sequencing of RBC-bound DNA illustrated distinct microbial communities, with RBC-bound DNA composition correlating with plasma IL-6 in patients with sepsis. Collectively, these findings unveil RBCs as overlooked reservoirs and couriers of microbial DNA, capable of influencing host inflammatory responses in sepsis.

  • Open Access

    Inflammatory and tissue injury marker dynamics in pediatric acute respiratory distress syndrome

    by Nadir Yehya, Thomas J. Booth, Gnana D. Ardhanari, Jill M. Thompson, L.K. Metthew Lam, Jacob E. Till, Mark V. Mai, Garrett Keim, Daniel J. McKeone, E. Scott Halstead, et al.

    BACKGROUND: The molecular signature of pediatric acute respiratory distress syndrome (ARDS) is poorly described, and the degree to which hyperinflammation or specific tissue injury contributes to outcomes is unknown. Therefore, we profiled inflammation and tissue injury dynamics over the first 7 days of ARDS, and associated specific biomarkers with mortality, persistent ARDS, and persistent multiple organ dysfunction syndrome (MODS). METHODS: In a single-center prospective cohort of intubated pediatric patients with ARDS, we collected plasma on days 0, 3, and 7. Nineteen biomarkers reflecting inflammation, tissue injury, and damage-associated molecular patterns (DAMPs) were measured. We assessed the relationship between biomarkers and trajectories with mortality, persistent ARDS, or persistent MODS using multivariable mixed effect models. RESULTS: In 279 patients (64 [23%] nonsurvivors), hyperinflammatory cytokines, tissue injury markers, and DAMPs were higher in nonsurvivors. Survivors and nonsurvivors showed different biomarker trajectories. IL-1α, soluble tumor necrosis factor receptor 1, angiopoietin 2 (ANG2), and surfactant protein D increased in nonsurvivors, while DAMPs remained persistently elevated. ANG2 and procollagen type III N-terminal peptide were associated with persistent ARDS, whereas multiple cytokines, tissue injury markers, and DAMPs were associated with persistent MODS. Corticosteroid use did not impact the association of biomarker levels or trajectory with mortality. CONCLUSIONS: Pediatric ARDS survivors and nonsurvivors had distinct biomarker trajectories, with cytokines, endothelial and alveolar epithelial injury, and DAMPs elevated in nonsurvivors. Mortality markers overlapped with markers associated with persistent MODS, rather than persistent ARDS. FUNDING: NIH (K23HL-136688, R01-HL148054).


  • Open Access

    Platelet factor 4 limits neutrophil extracellular trap– and cell-free DNA–induced thrombogenicity and endothelial injury

    by Anh T.P. Ngo, Abigail Skidmore, Jenna Oberg, Irene Yarovoi, Amrita Sarkar, Nate Levine, Veronica Bochenek, Guohua Zhao, Lubica Rauova, M. Anna Kowalska, et al.

    Plasma cell-free DNA (cfDNA), a marker of disease severity in sepsis, is a recognized driver of thromboinflammation and a potential therapeutic target. In sepsis, plasma cfDNA is mostly derived from neutrophil extracellular trap (NET) degradation. Proposed NET-directed therapeutic strategies include preventing NET formation or accelerating NET degradation. However, NET digestion liberates pathogens and releases cfDNA that promote thrombosis and endothelial cell injury. We propose an alternative strategy of cfDNA and NET stabilization with chemokine platelet factor 4 (PF4, CXCL4). We previously showed that human PF4 (hPF4) enhances NET-mediated microbial entrapment. We now show that hPF4 interferes with thrombogenicity of cfDNA and NETs by preventing their cleavage to short-fragment and single-stranded cfDNA that more effectively activates the contact pathway of coagulation. In vitro, hPF4 also inhibits cfDNA-induced endothelial tissue factor surface expression and von Willebrand factor release. In vivo, hPF4 expression reduced plasma thrombin-antithrombin (TAT) levels in animals infused with exogenous cfDNA. Following lipopolysaccharide challenge, Cxcl4 –/– mice had significant elevation in plasma TAT, cfDNA, and cystatin C levels, effects prevented by hPF4 infusion. These results show that hPF4 interacts with cfDNA and NETs to limit thrombosis and endothelial injury, an observation of potential clinical benefit in the treatment of sepsis.